Drug resistance malaria is a major challenge to control P. falciparum malaria in developing and low income countries particularly subSaharan Africa. It is the leading cause of morbidity and mortality [2] .
Structurally chloroquine is a 4-aminoquinoline which was introduced in the late 1940s. Chloroquine was used as a massive scale for malaria treatment and prophylaxis. Due to its efficacy, affordability and safety, chloroquine is a kind of standard treatment drug against malaria for a long time [3, 4] . Chloroquine is one of the cheapest and safest drugs ever used for malaria treatment [5] . It has one of the longest half-lives among antimalarials with approximately 60 d, which provides a chemoprophylactic effect during the drug elimination phase. It also exposes parasites to an extended time period after which chloroquine has fallen below the therapeutic concentration, which may select for drug-resistant parasites [4] .
There are two main mutations which characterize chloroquine resistance in P. falciparum such as the Pfcrt and Pfmdr1 mutations.
The (Pfcrt, K76T) and (Pfmdr1, N86N) are the most well-known markers for chloroquine resistance P. falciparum. P. falciparum chloroquine resistance at digestive food vacuole membrane has an association with each other. Pfcrt, K76T mutation occurs first and then another mutation followed. The (Pfcrt, K76T) point mutation yields more resistance than other Pfcrt point mutation [6] .
The association of K76T mutation with other mutations in Pfcrt gene gives different levels of chloroquine resistance [7] . The K76T mutation is selected first followed by its association with other mutations in Pfcrt gene.
The (Pfmdr1, N86Y) copy number and codon mutations are important factors for drug resistance P. falciparum. An increase in copy number of a gene enhances the level of drug resistance. The high copy number of a target gene found together with a codon mutation, and then the parasite possesses enhanced anti-malaria drug resistance level. A study showed that an increased Pfmdr1 copy number with wild type codon (N86) had mefloquine sensitivity. On the other hand, increased Pfmdr1 copy number with codon mutation (86Y) had a higher resistance level [8] . However, other recent studies showed that higher copy number of Pfmdr1 could cause resistance in mefloquine, artesunate and lumefantrine while low copy number was sensitive to in vitro test regardless of codon mutation [9] . Pfmdr1 polymorphism showed no relationship in in vitro susceptibility of these drugs [10] . Pfmdr1 copy number variation is more frequent event than Pfmdr1 codon mutation [11] .
Strong association was reported between K76T and N86Y mutations for chloroquine resistance [6, 12] . When (Pfcrt, K76T) and Pfmdr1 wild type (N86) occur together, the parasite shows resistance to chloroquine. On the other hand, when Pfcrt-K76T occurs with Pfmdr1 mutant type (86Y), the parasite shows resistance to chloroquine, but (Pfcrt, K76) and (Pfmd1, N86) do not have resistance to chloroquine. This implies that the presence of (Pfcrt, K76T) mutation is pre-condition for the Pfmdr1 parasite to develop multi-drug resistance property against chloroquine and also Pfmdr1 increases the level of chloroquine resistance having synergetic effect with (Pfcrt, K76T). High parasite population with (Pfcrt, K76T) mutation favours the emergence of (Pfmdr1, N86Y) mutation [13] . Chloroquine resistance reached at fixation stage after the development of resistance [14, 15] . The fixed population of chloroquine resistant P. falciparum will be continued in areas where P. falciparum and Plasmodium vivax (P. vivax) are co-endemic [16] .
Chloroquine, primaquine and quinine were the most popular anti-malarial drugs for malaria treatment in Ethiopia before 1998. [17] .
After the banning of sulfadoxine/pyrimethamine, Coartem is recommended to treat complicated malaria and mixed infections.
Since 2005 up to date chloroquine, artesunate, quinine and Coartem are in use to treat malaria [17, 18] . Chloroquine is still in use to treat uncomplicated malaria particularly P. vivax [17, 18] .
In the study area P. falciparum is common Plasmodium species and self-treatment is also common, so there is a danger that parasites develop resistance to Coartem and chloroquine [18] . The treatment of malaria in Ethiopia is done by chloroquine and Coartem nationwide.
Coartem is given for complicated malaria and chloroquine is given for uncomplicated malaria especially for P. vivax infections. The treatment of P. vivax by using chloroquine as first-line drug might increase the prevalence of chloroquine transporter gene point mutation and P. falciparum multi-drug resistance. Chloroquine is incompletely withdrawn from the study area. Hence the (Pfcrt, K76T) and (Pfmdr1, N86Y) mutation would have been fixed in P. falciparum population. The prevalence of chloroquine resistance molecular markers for P. falciparum has not been established in the study area. Therefore, the prevalence level of chloroquine resistance point mutation at (Pfcrt, K76T) and (Pfmdr1, N86Y) copy number variants were determined as critical factors for future malaria treatment in the study area.
Method and materials

Description of the study area
The study was conducted in six health centres in Dembia District 
Ethical clearance
The research proposal was submitted to University of Gondar
Natural and Computational Science College Ethical Review
Committee for Ethics approval. The Committee approved the proposed research is ethically cleared after thorough consideration of the proposed research proposal. Consent form was prepared for study participants. The purpose of this study was explained for participants and parents/guardians in their mother tongue before being recorded in the study. Those who did not consent were not included in the study. In agreement with clinics and hospital the cost of drug for treating positive patients were covered by the clinics and hospital.
Study design
The study was cross sectional. It was conducted during malaria transmission season (September to December, 2013). Malaria transmission is seasonal in Ethiopia, which is peak during autumn, September to December, and spring seasons, April to May. Six clinics (Tseda, Makisegnit, Chuahit, Aymba, Kola Diba and Sankisa) and one hospital (Metemma Hospital) were used as the study sites to collect samples from outpatients.
Study participants
Patients who attended the health institutions during study period were recruited for the study. Participants, who were between six months and seventy years old, were included in the study. Infants, under six months of age and pregnant women were excluded.
Patients, who were reported as P. falciparum positive during health service, were asked for consent to participate in the study by health professionals. Finger pricks were done, by health professionals, for those patients who consented to participate in the study.
Sampling
After finger pricking, two spots of blood samples were prepared on Whatman 3MM filter paper from each study participant. The blood spots were prepared by dropping three to four blood drops per spot on a piece of filter paper. In total, 168 blood samples were collected from all study sites (Tseda, n=14; Makisegnit, n=14; Sankisa, n=33, Chuahit, n=6; Kola Diba, n=32, Aymba, n=31; Metemma Hospital, n=38). The spots were properly labelled, air dried. Silica gel was added inside each plastic bag to prevent humidity. In order to avoid cross contamination one plastic bag was used for one filter paper.
The cards were collected in sealed plastic bag and transported to Kenya Medical Research Institute for molecular analysis.
Parasite DNA extraction
A piece of dried blood spot of approximately 2-3 mm in size was cut out with sterile scissors. The pieces were placed in sterile 1.5 mL extraction tubes using flamed forceps. High pure PCR template preparation kit (Version 20; Roche diagnostics, GmbH, Germany) was used to extract parasite DNA from dried blood spots. The extraction was done according to the manufacturer's instructions.
The extracted DNA was stored in -20 °C freezer until used for PCR.
Real-time PCR condition and amplification
Real-time PCR is an advanced PCR type over convetional PCR.
It is assisted by software for monitoring of the progress of DNA amplification. It does not depend on end product analysis. The progress of DNA amplification can be easily observed during the amplification reaction. In addition, real-time PCR is helpful for exclusion of primer-dimers and non-specific amplifications and, melting curve analysis is applied in real-time PCR. Real-time PCR helps to quantify the target gene and takes less time than convetional PCR. Therefore, in order to achieve the three objectives real-time PCR was used in the study. combined annealing and extension at 55 °C for 30 seconds followed by scanning the amplification product. This one step PCR runs for continuous 40 cycles. The PCR products were immediately subjected for melting to generate melting curves.
The melting process occurs when double stranded DNA formed after PCR amplification is dissociated at high temperature and as it melts the SYBR Green I dye fluorescent gradually decreases because the dye no longer stays being attached to the double stranded DNA.
This phenomenon detected by the Exicycler software and the software gave melting curves which had sharp turning point at the maximum melting temperature of each double stranded PCR amplification products. Therefore, each PCR product has specific "melting point"
and hence temperature profiling is used for identification of PCR products.
Melting curve analysis and primer-dimers
Primer-dimers occur when two PCR primers either same sense primers or sense and anti-sense primers bind to each other instead of to the target. Melting curve analysis identified the presence of primer-dimers because PCR amplicon is usually higher in length than primer-dimers. Therefore it has higher "melting temperature" 
Real-time PCR amplification for (Pfcrt, K76T) identification
The amplification of (Pfcrt, K76T) gene was employed using published primer pairs CRT-F (5'-TGA CGA GCG TTA TAG AG-3') and CRT-R (5'-GTT CTT TTA GCA AAA ATT G-3') [19] .
The amplification was done at 25 µL reaction volume. AccuPower 2x
GreenSta rTM qPCR Master mix (12.5 µL), 2 µL (10 pmole) forward primer, 2 µL (10 pmole) reverse primer, 3.5 µL DEPC-distilled water and 5 µL DNA template were used. NTC was included to control formation of primer-dimers.
Chloroquine resistant and sensitive P. falciparum strains (W2, D6
and 3D7) obtained from Kenya medical research institute malaria laboratory were used as controls in order to identify wild type and mutant type clinical samples. These controls were included in each PCR run throughout the experiment. An artificial mix of DNA extracted from these strains were made in different ratio in order to determine the efficiency and sensitivity of the assay to identify the wild type (Pfcrt, K76) and mutated type (Pfcrt, 76T) at different concentration levels. The ratios of strain W2 to strain D6 were (10 µL:10 µL, 5 µL:10 µL) and strain W2 to strain 3D7 were (10 µL:10 µL, 5 µL:10 µL). The mixing of the two strains was made to obtain the optimum detection threshold of the assay for genotyping (Pfcrt, K76T). The melting curves obtained from artificial mixed resistant strain with sensitive strain, and melting curves obtained from clinical samples were compared for confirmation purpose.
Melting curve analysis for (Pfcrt, K76T) identification
Melting curve analysis is useful for identification of wild and mutant genotypes of (Pfcrt, K76T). Since the melting curve shapes and peaks are different in these two genotypes, the curve and specific temperature profile enable to discriminate K76 and 76T
genotypes. Therefore, after amplification of the template DNA the 
(Pfmdr1, N86Y) and copy number determination by qPCR
Real-time PCR quantification of the target gene is better quantified when the template is short usually less than 200 bp. Therefore, in this study the Pfmdr1 amplification and copy number variation were determined from 178 bp long template DNA. In order to obtain short template newly designed primer pairs (forward 5'-GAT GGT AAC CTC AGT ACT-3' and reverse 5'-CTC CTG ATA ATA CAG CAC-3') were used with dual labelled single probe (5'-TET-ACC TAA ATA CAT GTT CTT T-3'-BHQ1). The probe was used to differentiate the mutant and wild type of the samples at (Pfmdr1, N86Y) codon. The labelled probe complements to the codon mutation specific region of the (Pfmdr1, N86Y). Fluorescence can be detected from the complementation of the probe with template because the quencher and reporter dyes fluoresce only when there is complementation between the target and the probe sequences. The probe sequence was obtained from published paper [20] .
In order to determine the copy number variation targeted in (Pfmdr1, N86Y) position, these newly designed qPCR primer pairs flanking in the complete mRNA (coding DNA sequence) regions of P. falciparum (3D7 strain) at chromosome five were used. Pfmdr1
or Polyglycoprotein 1 is coded by the gene located at chromosome five in P. falciparum genome and is responsible for multidrug resistance development in P. falciparum. The 3D7 strain sequence was selected for primer design because this strain is fully sequenced and representative for P. falciparum genome study. Pfmdr1 develop due to functional Polyglycoprotein1, therefore, non-functional sequences were excluded during the primer design.
The FASTA sequence was browsed from NCBI (www.ncbi.nlm.
nih.gov/) at GenBank accession number (XM_001351751) and pasted in the Integrated DNA Technology Primer Quest (www.
idtdna.com). After copy-pasting the FASTA sequence format, the parameters such as primer length, product length, GC content, Tm of primer, Tm of product and salt concentration were adjusted from drop down menu of the software. After designing the new primer pair, it was analyzed for Tm mismatch, self-dimer formation (homodimer), hairpin formation, and hetro-dimerization. The analysis was done by IDT Oligo analyser online (www.idtdna.com) and finally, "blastn" was done for the new primer pair from NCBI. After these all process the primer pairs were validated to be used for absolute quantification of the target gene for copy number variation.
The amplification of (Pfmdr1, N86Y) was done at 25 µL reaction volume of which 12.5 µL AccuPower 2× GreenStar TM qPCR Master mix, 2 µL (10 pmole) forward primer, 2 µL (10 pmole) reverse primer, 2 µL single probe, 1.5 µL DEPC-distilled water and 5 µL DNA template were used. Non-template control was included to control formation of primer-dimers.
Chloroquine resistant and sensitive P. falciparum strains (Dd2, W2, D6 and 3D7) obtained from Kenya medical research institute malaria laboratory were used as controls in order to determine copy number variation in clinical samples. These controls were included in each PCR run throughout the experiment in triplicated.
Absolute quantification of Pfmdr1 (N86Y) copy number variation
The standard curve was built from P. falciparum gDNA. Ten-fold serial dilution of the stock DNA was obtained by using the following formula based on the above concentration of template DNA.
Where: C 1 refers to stock concentration (15750 pg/µL); V 1 is required volume; V 2 refers to 100 µL; C 2 refers to 4000 pg/µL
Then the value of V 1 is 25.4 µL. In order to obtain the 100 µL dilution a difference of 25.4 µL from 100µL diluent is needed. The volume of diluent is 74.6 µL. Ten-fold serial dilution was prepared from the stock DNA (Table 2 ) and standard curve was built from the diluted DNA sample. The copy numbers were calculated using the above formula from DNA input concentration which was determined by the PCR.
Molecular weight of DNA is 660 g per mole per base pair and the amplicon length is 178 in base pair. Finally, the copy number ratio of positive controls (Dd2, W2 and D6) to 3D7 and samples to 3D7 were calculated manually in order to obtain copy number variation or fold difference among the calibrator 3D7 strain, positive controls and clinical samples. In other words the ratio of input template concentration of the samples and positive controls to the input template concentration of the 3D7 strain was determined. The ratio gives the fold difference between the sample and the reference strain 3D7. The 3D7 strain has single copy of Pfmdr1 gene per haploid genome. Therefore, if the sample had more copies than 3D7 it would be considered as multi-copy. In contrast, if the sample had less or equal copy with 3D7, the sample would be considered as single.
For instance, the copy number of 3D7 strain at 4000 pg/µL input concentration of DNA template was calculated as follows: The remaining values for clinical samples are computed in the same way in order to get the copy number variations.
Results
Pfcrt (K76T) identification and Pfmdr1 (N86Y) copy number determination
In the study 133 samples were re-confirmed by SYBR Green I-based real-time PCR as P. falciparum positive samples. Those samples were analysed further for (Pfcrt, K76T) genotyping and (Pfmdr1, N86Y) copy number determination.
The P. falciparum chloroquine transporter gene was targeted for 
Pfmdr1 (N86Y) amplification and copy number variation
The genotyping of wild type (Pfmdr1, N86) and mutant type The melting curve analysis was not successful for further analysis of these polymorphisms. The failure of melting curve analysis could be due to loose complementation between the probe and the template hence it melted rapidly before formation Cycle   2  4  6  8  10  12  14  16  18  20  22 24  26  28 30  32  34  36  38  40 Primer dimer and non specific amplification Figure 5 . Amplification curves of (Pfmdr1, N86Y) gene in log scale form.
Number of samples A total of 133 samples were analysed further for determination of the (Pfmdr1, N86Y) copy number variation. Among the 133 samples 73 (54.89%) samples were confirmed as multicopy variants of (Pfmdr1, N86Y) having copy numbers of the target gene from 1.5 copies to 4.471 copies per genome and the remaining 60 (45.11%) were confirmed as single copy variants of (Pfmdr1, N86Y) having copy numbers less than 1.5 copies per genome ( Figure 7) .
The multi-copy number variants of (Pfmdr1, N86Y) were categorized as medium copy number variants and higher copy number variants. In this category 34 (25.56%) were medium copy number variants of (Pfmdr1, N86Y) having copy numbers less than 2.5 copies per genome and 38 (28.57%) were with higher copy number variants of (Pfmdr1, N86Y) having 2.5 copies or more copy numbers per genome (Figure 8 ).
The minimum and maximum copy numbers per genome were 0.497 (single copy) and 4.741 (multi-copies), respectively.
Positive controls obtained from Kenya medical research institute malaria laboratory were included in the assay. The controls were Dd2 P. falciparum strain which is known to have multiple copy numbers of (Pfmdr1, N86Y), and W2 and D6 P. falciparum strains which possess single copy number of (Pfmdr1, N86Y). The copy number variants of the positive controls were consistently found as single and multi-copy in each experimental runs.
Discussion
This is the first study conducted to determine prevalence of chloroquine transporter gene point mutations at (Pfcrt, K76T) and (Pfmdr1, N86Y) copy number variation in the study area.
The (Pfcrt, 76T) point mutation is the marker which shows the status of chloroquine resistant malaria. The high prevalence level of this mutation is an indicator for the spread of drug resistant P. falciparum population in the study area. There are no related data done for the prevalence level of chloroquine resistant malaria in the study area for comparison the result obtained from this study showed high prevalence of (Pfcrt, 76T) mutation, but not statistically significant (P>0.05). The (Pfcrt, 76T) point mutation is well established molecular marker for chloroquine resistance level and the prevalence rate of the resistant parasite (Pfcrt, 76T) is the first mutation to be occurred and shows high level of resistance compared to the rest point mutations at Pfcrt gene [22] . Therefore, the higher the prevalence of this mutation, the more risk of malaria and challenging for drug resistance malaria control.
In addition, high prevalence of (Pfcrt, 76T) suggests that the presence of drug pressure or other factors which favours (Pfcrt, 76T) mutation.
Chloroquine was withdrawn from the study area since 2004 for treatment of P. falciparum malaria [17] . If chloroquine was completely withdrawn, the parasite would have been reverted to (Pfcrt, K76) and chloroquine could be used for treatment of P. falciparum. Studies in Kenya, Tanzania and Malawi showed the conversion of (76T) to (K76) and reduction of (Pfcrt, 76T) prevalence [23, 24] . The use of artemesinin combination therapy (ACT) increased throughout Africa [25] .
Therefore, the prevalence of 76T point mutation was expected to be reduced in Africa. However, in Southern Ethiopia one study showed high prevalence of (Pfcrt, K76T) and (Pfmdr1, N86Y) point mutations [26] . The drug chloroquine could be used again as combination or single treatment drug to treat malaria caused by P. falciparum where chloroquine mutation prevalence is very low or disappeared [22] . The current study and another study done in Ethiopia showed a high prevalence level of chloroquine resistant P. falciparum point mutation and hence re-use of chloroquine for P. falciparum treatment in the Ethiopian context is not advisable. In this study high prevalence of P. falciparum multidrug resistance copy number variants were found, but it was not significant statistically (P>0.05). Copy number variation exists among P. falciparum strain regardless of codon mutation.
Parasites do have coping mechanism against drug pressure and the mechanism is highly dynamic across P. falciparum population.
When chloroquine was a treatment drug for P. falciparum the parasite was able to survive and become fully resistant to chloroquine. Codon mutation and/or copy number variation is/ are the most common means of resistance development against the most used treatment drugs. Studies showed that copy number variations occur first and the P. falciparum becomes tolerant for many drugs. The higher the copy numbers of (Pfmdr1, N86Y) gene is, the more tolerant against treatment drugs. Even the uses of combination drugs become risky for effective treatment. High population of multidrug resistance mutation and copy number variation in P. falciparum develop resistance for many drugs like mefloquinine, lumefantrine and/or artemisinin derivative combination drugs such as Coartem (artemether/lumefantrine).
An in vitro study done in Ghana showed that nascent clones of P. falciparum manifested by reduced susceptibility to artemisinin derivatives [27] . Since lumefantrine and mefloquinine have physiochemical similarity, therefore, resistance to mefloquinine can be modulated by lumefantrine. A study done in Kenya showed that (Pfmdr1, N86Y) has association with mefloquinine response [28] . Another in vitro study in Cambodia-Thailand border showed that parasites with higher copy number showed significantly reduced susceptibility to mefloquinine, lumefantrine and artesunate. However, Pfmdr1 polymorphism showed no relationship in in vitro susceptibility of these drugs [10] .
Pfmdr1 copy number variation is more frequent event than Pfmdr1 codon mutation [11] . A knockdown study done on Pfmdr1 gene copy number showed reduced susceptibility to mefloquinine, lumefantrine and artesunat in an in vitro susceptibility test. In contrast, this knockdown study showed that parasite line with low copy numbers had heightened susceptibility to artesunate and lumefantrine [9] . Parasites with single copy number are sensitive for mefloquinine, lumefantrine and artesunate. These drugs can be used for combination therapy where the population of P. falciparum with single copy number of Pfmdr1 gene are fixed [15] .
The study of copy number variation in P. falciparum population is very vital for monitoring of resistance malaria particularly where mefloquine and lumefantrine are used for combination therapy (ACT). Pfmdr1, are promising tools for the surveillance of drug resistance [29] . Pfmdr1 copy number is not only strongly associated with recrudescence to artesunate-mefloquine but also with Coartem failure [8] .
In the Ethiopian context Coartem is the treatment drug for uncomplicated malaria especially for P. falciparum. Since Coartem is an ACT drug which has lumefantrine component the presence of strains with high copy number variation in P. falciparum seems inevitable. The current study found high prevalence of multi-copy number variants in the study area. The parasite shifts from high Pfmdr1 copy number to low copy number or vice versa depending on the drug pressure in the parasite population. P. falciparum with higher copy number is spread and favoured when mefloquinine, mefloquinine combination or drugs physiochemical similarities to mefloquinine are used for treatment of P. falciparum. In contrast, P. falciparum population with higher copy shifts to population of parasites with low copy because withdrawal of mefloquinine pressure has fitness disadvantage for continuation of mefloquinine resistant P. falciparum [11] .
In this study a high prevalence of P. falciparum with a higher Pfmdr1 copy number variants were found. This showed that fixation of the P. falciparum population with fitness advantage with possessing multiple copy of (Pfmdr1, N86Y). It is, indirectly, an alert that there is drug pressure which favours these populations in the study area. The reasons could be incomplete withdrawal of chloroquine, use of lumefantrine combination drug (Coartem), misdiagnosis of single infections and mixed infections. It was found a high prevalence of mixed infection and misdiagnosed P. falciparum which would have been treated by undesired drug that could contribute for fixation of the resistant P. falciparum.
Although, it is not statistically significant, a high prevalence level of chloroquine resistant P. falciparum was obtained. The (Pfcrt, K76T) point mutation showed fixation of previous chloroquine resistant P. falciparum population after withdrawal of chloroquine in the study area. The prevalence of (Pfmdr1, N86Y) copy number variant was not statistically significant, but it was highly spread and found to be an indicator of the evolutionary path shift from resistant P. falciparum for monotherapy to resistant P. falciparum population against combination drug therapy.
Therefore, a high copy number variation is shown to be a risk factor for use of combination drugs for treatment of malaria.
Further, studies should be done to determine the prevalence level of P. falciparum chloroquine resistance point mutations and its fixation. It is critical for continuation or discontinuation of chloroquine use at a national level. Comprehensive molecular surveillance is needed in order to control the spread of Pfmdr1 copy number variants in P. falciparum population and it could be useful indicator of resistance development against combination therapy because Pfmdr1 copy numbers are increased when mefloquinine and related drugs are used for treatment of P. falciparum.
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Comments
Background
This study was conducted in the endemic area of P. falciparum where self-treatment is common, so it is danger that parasite develop resistance to Coartem and chloroquine (a first line drug).
The (Pfcrt, K76T) and (Pfmdr1, N86N) are the most known markers for chloroquine resistance P. falciparum. Prevalence level of chloroquine resistance point mutation at (Pfcrt, K76T) and (Pfmdr1, N86Y) copy number variants were determined as marker for this study area.
Research frontiers
The present research work depicts prevalence of chloroquine resistance point mutation at (Pfcrt ,K76T) and (Pfmdr1, N8Y) copy number determination by using SYBR Green I qPCR. The method has been publish but this is the first report of prevalence of (Pfcrt, K76T) and (Pfmdr1, N86Y) in this area after chloroquine was withdrawn from this area.
Related reports
There is another study report in 2014 for the first time the return of chloroquine sensitive P. falciparum in Southern and Eastern Ethiopia (not the same area of this study). The Pfcrt K76 CQsensitive allele was observed in 84.1% of the investigated P. falciparum clinical isolates.
Innovations and breakthroughs
The present study gives a chloroquine drug resistance surveillance report with drug resistance warning message for chloroquine drug pressure.
Applications
This surveillance study has found the prevalence point mutation at (Pfcrt, K76T) and high copy number of Pfmdr1, N86Y in the study area. Although the result showed that it was not statistically significant. It might be alert that chloroquine was incompletely withdraw from this area and it could be a risk of drug resistance.
Peer review
This is the first study conducted to determine the chloroquine transporter gene point mutations at (Pfcrt, K76T) prevalence and (Pfmdr1, N86Y) copy number variation in the study area. In this study high prevalence of P. falciparum with a higher Pfmdr1 copy number variants were found. Surveillance studies to investigate resistance markers of Pfmdr1 and Pfcrt genes of P. falciparum in the same geographic area may help to assess the prevalence of antimalarial resistance.
